TL;DR: The Centers for Medicare & Medicaid Services modified NCD 70 governing adult liver transplantation coverage policy, with an effective date of January 9, 2026. Here's what billing teams need to know before submitting claims.
CMS adult liver transplantation coverage policy under NCD 70 Medicare has been updated. This NCD 70 Medicare policy covers adult liver transplantation as an inpatient hospital benefit for Medicare beneficiaries with end-stage liver disease and select malignancies. No specific CPT or HCPCS codes are listed in this policy document — but the coverage criteria, facility approval requirements, and malignancy indications carry real financial exposure for transplant centers billing Medicare.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Adult Liver Transplantation |
| Policy Code | NCD 70 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | High |
| Specialties Affected | Transplant surgery, hepatology, oncology, inpatient hospital billing |
| Key Action | Confirm your facility holds current CMS institutional approval before billing adult liver transplant claims under Medicare |
CMS Adult Liver Transplantation Coverage Criteria and Medical Necessity Requirements 2026
The core of this coverage policy hasn't changed dramatically in structure, but the January 9, 2026 update makes it the current operative version billing teams must reference. The real issue here is that adult liver transplantation billing is high-dollar, high-scrutiny, and the medical necessity criteria are layered by diagnosis, tumor characteristics, and facility status.
CMS covers adult liver transplantation under three main clinical scenarios. Each has its own effective date, its own criteria, and its own exposure if you get it wrong.
End-stage liver disease (non-malignancy): Coverage has been in place since July 15, 1996 for end-stage liver disease excluding hepatitis B or malignancies. The December 10, 1999 expansion added hepatitis B-related end-stage liver disease. Both require the patient to be treated at a CMS-approved facility.
Hepatocellular carcinoma (HCC): CMS covers liver transplantation for HCC effective September 1, 2001, but only when all five of these conditions are met:
| # | Covered Indication |
|---|---|
| 1 | The patient is not a candidate for subtotal liver resection |
| 2 | The tumor is 5 cm or smaller in diameter |
| 3 | There is no macrovascular involvement |
| 4 | There is no extrahepatic spread to lymph nodes, lungs, abdominal organs, or bone |
| 5 | The transplant is performed at a CMS-approved facility |
These are the Milan criteria in practice. If your documentation doesn't address all five points, your claim is exposed. Don't submit a liver transplant claim for HCC without pathology reports and imaging that directly speak to each criterion.
MAC-level malignancy coverage (effective June 21, 2012): Medicare Administrative Contractors can determine coverage for three specific malignancies in their jurisdictions:
| # | Covered Indication |
|---|---|
| 1 | Extrahepatic unresectable cholangiocarcinoma (CCA) |
| 2 | Liver metastases due to neuroendocrine tumor (NET) |
| 3 | Hemangioendothelioma (HAE) |
This is where billing gets complicated. Whether CCA, NET, or HAE liver transplantation is covered depends on your MAC — not just CMS national policy. Check your MAC's local coverage determination before billing these cases. If your MAC hasn't issued a policy on these indications, the claim outcome is genuinely uncertain.
Prior authorization requirements for liver transplantation under Medicare are not explicitly addressed in NCD 70, but facility approval is a hard prerequisite. No CMS facility approval equals no coverage — period. That's a different mechanism than a typical prior authorization, but the financial effect is the same.
CMS Adult Liver Transplantation Exclusions and Non-Covered Indications
CMS is explicit here. Adult liver transplantation for malignancies not listed in the nationally covered indications — and not covered by a MAC determination — is nationally non-covered.
The policy states this plainly: "Adult liver transplantation for other malignancies remains excluded from coverage." If a patient has a primary or metastatic malignancy that doesn't fall into HCC, CCA, NET, or HAE, the transplant is not covered under Medicare as a national policy. Some MACs may have gone further, but that's their jurisdiction, not national policy.
This is the exclusion that matters most financially. Transplant centers sometimes attempt liver transplantation for rare malignancies where evidence is emerging. Under the current coverage policy, those cases face denial unless the patient's MAC has an active policy expanding coverage. Get that MAC-level determination in writing before the procedure. If you're not sure how this applies to your payer mix and case volume, loop in your compliance officer before January 9, 2026.
Coverage Indications at a Glance
| Indication | Status | Coverage Effective | Notes |
|---|---|---|---|
| End-stage liver disease (non-hepatitis B, non-malignancy) | Covered | July 15, 1996 | CMS-approved facility required |
| End-stage liver disease with hepatitis B | Covered | December 10, 1999 | CMS-approved facility required |
| Hepatocellular carcinoma (HCC) — Milan criteria met | Covered | September 1, 2001 | All five tumor/staging criteria must be documented |
| Extrahepatic unresectable cholangiocarcinoma (CCA) | MAC discretion | June 21, 2012 | Coverage depends on your Medicare Administrative Contractor |
| Liver metastases from neuroendocrine tumor (NET) | MAC discretion | June 21, 2012 | Coverage depends on your Medicare Administrative Contractor |
| Hemangioendothelioma (HAE) | MAC discretion | June 21, 2012 | Coverage depends on your Medicare Administrative Contractor |
| Other malignancies | Not Covered | National exclusion | No national coverage; MAC expansion not guaranteed |
| Follow-up care post-covered transplant | Covered | Concurrent | Must be reasonable and necessary under Medicare guidelines |
| Follow-up care post-non-covered transplant | Covered (limited) | Concurrent | Only for items and services that are reasonable and necessary |
| Re-transplantation (following covered transplant) | Covered | Concurrent | Must be reasonable and necessary |
| Immunosuppressive drugs | See separate policy | Concurrent | Refer to Medicare Benefit Policy Manual Ch. 15 §50.5.1 and Claims Processing Manual Ch. 17 §80.3 |
CMS Adult Liver Transplantation Billing Guidelines and Action Items 2026
The update is live as of January 9, 2026. Here's what your team needs to do now.
| # | Action Item |
|---|---|
| 1 | Verify your facility's CMS institutional approval status. This is the prerequisite for every adult liver transplant claim you submit to Medicare. If approval has lapsed or was never formally obtained, your claims will deny. Pull the approval documentation and confirm it's current before January 9, 2026. |
| 2 | Audit HCC transplant documentation against all five coverage criteria. For every hepatocellular carcinoma transplant case, confirm that the medical record explicitly addresses resection candidacy, tumor size (≤5 cm), macrovascular involvement, and extrahepatic spread. A claim denial on an HCC transplant almost always traces back to incomplete documentation on one of these five points. |
| 3 | Contact your MAC for CCA, NET, and HAE indications. CMS delegates these coverage decisions to Medicare Administrative Contractors. Pull your MAC's current policy on extrahepatic unresectable cholangiocarcinoma, neuroendocrine tumor liver metastases, and hemangioendothelioma before you bill these cases. Don't assume national coverage exists — it doesn't for these three. |
| 4 | Separate your follow-up care billing from the transplant claim. Follow-up care post-transplant is covered, but it must be billed as reasonable and necessary services in its own right. Don't bundle post-transplant services incorrectly. The same applies to re-transplantation — document medical necessity separately, even though the original transplant was covered. |
| 5 | Review immunosuppressive drug billing separately. NCD 70 explicitly cross-references Medicare Benefit Policy Manual Chapter 15, §50.5.1 and the Medicare Claims Processing Manual Chapter 17, §80.3 for immunosuppressive drugs. Your pharmacy and billing teams should be following those specific guidelines — not treating immunosuppressives as automatic add-ons to the transplant claim. |
| 6 | Flag any non-listed malignancy cases before billing. If a patient received a liver transplant for a malignancy that isn't HCC, CCA, NET, or HAE, the claim will likely deny under national policy. Review these cases with your compliance officer and check your MAC's jurisdiction before submitting. Reimbursement on these cases is not guaranteed and the financial exposure is significant. |
| 7 | Confirm your internal coding workflow reflects the January 9, 2026 effective date. Update your charge capture documentation, coder reference guides, and any internal billing guidelines to cite NCD 70 as updated January 9, 2026. Using an outdated policy citation on an audit response is avoidable and looks sloppy. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Adult Liver Transplantation Under NCD 70
The Centers for Medicare & Medicaid Services did not include specific CPT, HCPCS, or ICD-10 codes in the published NCD 70 policy document. This policy does not list applicable procedure or diagnosis codes.
For adult liver transplantation billing, your coding team should reference:
- The current AMA CPT code set for liver transplant procedure codes
- ICD-10-CM codes for the underlying diagnosis (end-stage liver disease, HCC, CCA, NET, HAE, as applicable)
- Your MAC's local coverage determination for any additional code-level guidance on CCA, NET, and HAE indications
- CMS claims processing transmittal TN 2513 for claims processing instructions
If you're building a charge master or coder reference sheet for liver transplant cases, work from your MAC's published guidance alongside this NCD. NCD 70 sets the coverage rules — your MAC and the AMA CPT codebook fill in the code-level specifics.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.